Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D609793-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,000.90 | |
D609793-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $4,000.90 |
Specifications & Purity | Moligand™ |
---|---|
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of TLR2;Agonist of TLR4 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
INCHI | InChI=1S/C52H100N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-38(56)34-42(57)53-45-48(61)47(60)41(72-52(45)74-76(66,67)68)37-69-51-46(49(62)50(40(36-55)71-51)73-75(63,64)65)54-43(58)35-39(32-29-26-23-20-17-14-11-8-5-2)70-44(59)33-30-27-24-21-18-15-12-9-6-3/h38-41,45-52,55-56,60-62H,4-37H2,1-3H3,(H,53,57)(H,54,58)(H2,63,64,65)(H2,66,67,68)/t38-,39+,40-,41-,45-,46-,47-,48-,49-,50-,51-,52-/m1/s1 |
---|---|
InChi Key | GOWLTLODGKPXMN-MEKRSRHXSA-N |
Canonical SMILES | CCCCCCCCCCC[C@H](CC(=O)N[C@H]1[C@H](O[C@@H]([C@H]([C@@H]1O)O)CO[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1NC(=O)C[C@@H](OC(=O)CCCCCCCCCCC)CCCCCCCCCCC)O)OP(=O)(O)O)OP(=O)(O)O)O |
Isomeric SMILES | CCCCCCCCCCC[C@H](CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1OP(=O)(O)O)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)OP(=O)(O)O)O)NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)O)O)O |
PubChem CID | 656812 |
ChEBI | CHEBI:34898 |
---|---|
ChEMBL Ligand | CHEMBL2105854 |
PubChem CID | 656812 |
CAS Registry No. | 171092-39-0 |
Enter Lot Number to search for COA:
1. Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF, Jeannin JF. (1999) Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats.. Clin Exp Metastasis, 17 (4): (299-306). [PMID:10545016] [10.1021/op500134e] |
2. Brandenburg K, Lindner B, Schromm A, Koch MH, Bauer J, Merkli A, Zbaeren C, Davies JG, Seydel U. (2000) Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity.. Eur J Biochem, 267 (11): (3370-7). [PMID:10824125] [10.1021/op500134e] |
3. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. (2007) Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.. Eur J Pharmacol, 563 (1-3): (1-17). [PMID:17383632] [10.1021/op500134e] |
4. Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, López JA, Corradin G. (2003) OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei.. Vaccine, 21 (19-20): (2485-91). [PMID:12744882] [10.1021/op500134e] |
5. Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M. (2013) Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.. BMC Cancer, 13 (13): (172). [PMID:23547558] [10.1021/op500134e] |